Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)
Constanze Elfgen(Witten/Herdecke University), Zsuzsanna Varga(Zurich Heart House), Ashutosh Kothari(Guy's and St Thomas' NHS Foundation Trust), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Cecily Quinn(University College Dublin), Stephanie Strobl, Simone Schrading(University of Bonn), Vesna Bjelic‐Radisic(Helios Universitätsklinikum Wuppertal), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), R. Huch(Kantonsspital Baden), Thomas Decker, G Kampmann, Sabine Zehbe(Hirslanden Klinik Stephanshorn), Rosaria Condorelli(Ente Ospedaliero Cantonale), P. J. van Diest(University Medical Center Utrecht), Peter Regitnig(Medical University of Graz), Michael Fuchsjäger(Medical University of Graz), Martina Maranta, Eva Maria Fallenberg(TUM Klinikum), Meike Körner, Simone Muenst(University Hospital of Basel), Martin Daniaux(BrustGesundheitZentrum Tirol), Jean‐Christophe Tille(Université Paris Sciences et Lettres), Sigurd Lax(Graz University Hospital), Sorcha McNally(St. Vincent's University Hospital), Uwe Güth(Breast Center), Cornelia Leo(Breast Center), Ritse M. Mann(Radboud University Nijmegen), Daniela Schwegler-Guggemos(Kantonsspital Aarau), Janina Kulka(Semmelweis University), Noemi Schmidt(University Hospital of Basel), Martin Sonnenschein(Engeriedspital), Christoph Tausch(Breast Center), Maria Bernathova(Medical University of Vienna)
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
June 17, 2023
Cited by 91
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k